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Accepted 16 March 2016Innate lymphoid cells (ILCs) play an important role in immunity, inﬂammation, and tissue remodeling and their
dysregulation is implicated in autoimmune and inﬂammatory disorders. We analyzed the impact of daclizumab,
a humanized monoclonal anti-CD25 antibody, on circulating natural killer (NK) cells and ILCs in a cohort of
multiple sclerosis patients. An increase in CD56bright NK cells and CD56hiCD16intermediate transitional NK cells
was observed. No signiﬁcant change in total ILCs or major ILC subpopulations was observed. These results reﬁne
our understanding of the impact of daclizumab on innate lymphoid cell populations.
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NK1. Introduction
Innate lymphoid cells (ILCs), a family composed of three functionally
distinct subsets, are increasingly appreciated to play important roles
in immunity, inﬂammation, and tissue remodeling as well as in the
pathogenesis of inﬂammatory, allergic and autoimmune disorders
(Hazenberg and Spits, 2014; Sonnenberg and Artis, 2015). Lymphoid
tissue-inducer (LTi) cells, a subpopulation of group 3 ILCs (ILC3), are im-
plicated in the formation of tertiary lymphoid follicles — structures of
accumulated lymphoid cells that arise in chronically inﬂamed adult tis-
sue (Grogan and Ouyang, 2012). In multiple sclerosis (MS), lymphoid
aggregates have been found at autopsy within the inﬂamed meninges
of a substantial portion of patients (Howell et al., 2011; Magliozzi
et al., 2007; Seraﬁni et al., 2004). One mechanism that has been sug-
gested for the genesis of these lymphoid aggregates is that LTi-like
ILC3s, found in the cerebrospinal ﬂuid, initiate and sustain formation
of these focal aggregates in the setting ofMS (Perry et al., 2012). Recent-
ly daclizumab, a humanized monoclonal antibody against CD25, has
been reported to reduce LTi cells in the circulation and cerebrospinal
ﬂuid of MS patients (Lin et al., 2015; Perry et al., 2012). Given the ex-
pression of CD25 by other ILC subsets, ILC2s in particular (Monticelli
et al., 2011; Sonnenberg et al., 2013), and the focus exclusively on
ILC3s in the previous studies, we sought to extend these reports by).
. This is an open access article underanalyzing circulating ILCs in a cohort of relapsing remitting MS
(RRMS) patients pre- and post-treatment with Daclizumab High Yield
Process (DAC HYP) using a FACS panel capable of identifying ILC popu-
lations based on current consensus deﬁnitions.2. Methods
2.1. PBMC samples
PBMC sampleswere collected in the SELECT clinical trial of DACHYP,
a form of daclizumab developed for subcutaneous administration
(Gold et al., 2013). SELECT is registered at ClinicalTrials.gov (Identiﬁer
NCT00390221). Whole blood samples were collected in CPT with sodi-
um heparin tubes (BD Biosciences, San Jose, CA), shipped at ambient
temperature without centrifugation to a central processing site where
PBMC isolation and cryopreservation were performed within 24–48 h
of collection.2.2. FACS analysis
Cryopreserved PBMC were rapidly thawed and stained using
Brilliant Violet buffer (BD Biosciences) and the FoxP3 Fix/Perm reagents
(eBioscience, SanDiego, CA) according tomanufacturers' instructions. A
minimum of 400,000 events were acquired on a BD Fortessa X20 ﬂow
cytometer and analyzed using FlowJo X software (TreeStar, Ashland,
OR). See Supplemental Table 1 for details.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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For comparison of repeated measurements within two identical
groups of patients, a paired Student's independent sample t-test was
performed (GraphPad Prism, San Diego, CA). A p value b 0.05 was con-
sidered signiﬁcant.3. Results
3.1. NK cell/ILC FACS panel validation
A 16-color FACS panel was designed to identify NK cell and ILC sub-
populations (Sup Fig. 1). Both fresh (n=10) and frozen (n=13) PBMC
from healthy donors were used to extensively validate the panel.
Three NK cell subpopulations were delineated based on CD56
and CD16 expression on CD45+ cells lacking lineage markers (Lin−;
CD3/CD5/CD10/CD14/CD19/CD115/CD123)-CD56bright NK cells
(Lin−CD56hiCD16−), CD56dim NK cells (Lin−CD56+CD16hi), and tran-
sitional NK cells (Lin−CD56hiCD16intermediate; CD56trans NK). Consistent
with published data, all NK subsets expressed T-bet, eomes, andGATA-3
(Sup Fig. 2). In addition, while all NK subpopulations lacked expression
of CD127, they expressed CD7, CD161, CD11c, CCR6, and CD122 and had
heterogeneous expression of CD25 (Sup Fig. 2 and data not shown).
Total ILCs (CD45+Lin−CD56−CD16−CD127+ cells) were deﬁned
by expression of CD127 on cells from within the CD45+Lin−CD56−
CD16− gate (Sup Fig. 1). Based on previously deﬁned consensus
markers, total ILCs were sub-divided into T-bet+ group 1 ILCs
(ILC1s), T-bet−GATA-3hiCD25+ group 2 ILCs (ILC2s), and T-
bet−GATA-3loCD25−RORγt+CCR6+ group 3 ILCs (ILC3s) (Sup Fig. 1)
(Sonnenberg et al., 2013; Spits et al., 2013). Preliminary analysis
revealed that RORγt staining was lost or degraded in frozen PBMC
samples from the SELECT study, possibly due to differences in handling
or cryopreservation. Because all human ILC3 subsets, unlike the
murine equivalents, uniformly express CCR6 (Cupedo et al., 2009;
Sonnenberg et al., 2013), and we observed a strong correlationFig. 1.DAC HYP-treatment results in increased representation of CD56bright and CD56trans NK ce
after 24weeks of treatmentwith DACHYP (bottom). Plots are gated on live CD45+ Lin− cells. G
gate), CD56trans (CD56hiCD16intermediate; green gate) and CD56dim (CD56+CD16+; blue gate). (B
CD45+ cells; right column) of the gated NK cell populations from placebo-treated MS patient
patients at baseline (BL) or after 24 weeks of treatment with DAC HYP (Wk24).between CCR6 and RORγt in freshly isolated healthy donor PBMC
(Sup Fig. 3 and data not shown), CCR6 expression was used to deﬁne
ILC3s in the T-bet−GATA-3− gate in frozen PBMC samples from the
SELECT study (Fig 2 and data not shown). Consistent with published
literature, ILC1s were T-bet+eomes+GATA-3lo, while ILC2s were
T-bet−eomes−GATA-3hi, and ILC3s were T-bet−eomes−GATA-
3loCCR6+ (Sup Fig. 4). Enhanced expression of CD25, CD127, and
CD161 was observed on ILC2s relative to the other ILC subsets (Sup
Fig. 4).
3.2. NK cell analysis
Paired patient PBMC samples from baseline (pre-treatment) and
week 24 (post-treatment) from 10 placebo-treated and 20 DAC HYP-
treated RRMS patients in the SELECT trial were analyzed. CD56bright
NK cells were signiﬁcantly increased in DACHYP-treated RRMSpatients
whenmeasured as a percentage of Lin− cells (p= 0.0024) and in abso-
lute numbers (normalized per 1 × 106 total CD45+ cells; p b 0.0001)
while the CD56dim NK cells remained unchanged (Fig. 1A and B). In-
creased percentages and absolute numbers of CD56trans NK cells were
observed in DAC HYP-treated RRMS patients (p b 0.0001). The expres-
sion of T-bet, eomes and GATA-3 on each NK cell subset did not change
with DAC HYP treatment (data not shown). These results were con-
ﬁrmed in a second cohort of PBMC samples from 10 placebo-treated
and 20 DAC HYP-treated patients in the SELECT trial (data not shown).
3.3. ILC analysis
No signiﬁcant differences were observed in the percentage or
absolute number of total ILCs, or of ILC1s, ILC2s, or ILC3s speciﬁcally
(Fig. 2A–E). A trend towards decreased percentages of ILC3s was ob-
served following treatment with DAC HYP (Fig. 2C); however, this did
not achieve statistical signiﬁcance (p = 0.1105). Similar results were
observed in a second cohort of PBMC samples from 10 placebo-treated
and 20 DAC HYP-treated patients in the SELECT trial (data not shown).ll subsets. (A) Representative plots of NK cell subsets from aMS patient at baseline (top) or
ates used to deﬁne populations under analysis are indicated: CD56bright (CD56hiCD16−; red
) Percentages (based on total Lin− cells; center column) and absolute numbers (per 1× 106
s at baseline (BL), 24 weeks post-treatment with placebo (Wk24), DAC HYP-treated MS
Fig. 2.DAC HYP-treatment does not alter the representation of Lin− ILC subsets. Representative plots identifying (A) CD45+Lin−CD56−CD16− (double negative; DN) cells; (B) total ILCs;
(C) ILC1s; (D) ILC2s; and (E) ILC3s (left column). Percentages (center column) and absolute number (per 1 × 106 CD45+ cells; right column) are shown for each cell population (A–E). For
DNand total ILC populations, the percentages are based on theparent population (total CD45+Lin− andDN, respectively)while the ILC1, ILC2, and ILC3populations are all represented as a
percentage of total ILCs.
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scription factors (T-Bet, eomes, GATA-3) or cell surface proteins (CD7,
CD11c CD127, and CD161) on any ILC subset following DAC HYP treat-
ment (data not shown). Consistent with the effects of DAC HYP on
other CD25-expressing cell populations, CD25 mean ﬂuorescent inten-
sity (MFI) was signiﬁcantly decreased on ILC2s following treatment
with DAC HYP (p = 0.005) (Sup Fig. 5).4. Discussion
The 16-color FACS panel reported here simultaneously quantiﬁes
major NK cell and ILC subsets. Reproducing previously published results
(Bielekova et al., 2006;Martin et al., 2010), we observed a signiﬁcant in-
crease in CD56bright NK cells during DAC HYP therapy. Additionally, we
observed a signiﬁcant increase in CD56hiCD16intermediate transitional
44 G.O. Gillard et al. / Journal of Neuroimmunology 294 (2016) 41–45NK cells, a ﬁnding that has not been reported previously. CD56bright and
CD56trans NK cells have been proposed to be precursors or functional in-
termediates of CD56dim NK cells (Béziat et al., 2011). It is interesting to
note that in contrast to the CD56bright and CD56trans NK cells, the num-
ber of CD56dimNK cells remained constant in DACHYP-treated patients.
While severalmechanisms could account for this observation, including
altered tissue homing of fully differentiated CD56dim NK cells, limited
niche for supporting ‘mature’ cells, and chronic IL-2 signaling
preventing thematuration of ‘precursor’ populations, it is worth consid-
ering whether this observation indicates that CD56bright and CD56trans
NK cells are not immature precursors to CD56dim NK cells (Freud et al.,
2014), but rather differentially regulated, and mature, NK cell subsets.
Two previous publications have addressed the effects of DAC HYP
therapy on ILCs.While both reports showed a reduction in total circulat-
ing ILCs (Perry et al., 2012; Lin et al., 2015), in contrast to Perry et al.,
2012, Lin and colleagues did not observe statistically signiﬁcant alter-
ations in circulating LTi-like cells (a subpopulation of ILC3s) in response
to DAC HYP treatment (Lin et al., 2015). However, Lin et al. did report
decreased LTi-like cells in the cerebral spinal ﬂuid (CSF) of DAC HYP
treated patients (Lin et al., 2015). Like Lin et al., we did not observe sig-
niﬁcant alterations in the percentage or absolute numbers of circulating
ILC3s, including LTi-like cells, as a result of DACHYP therapy.While all of
the studies are consistent on the effects of DAC HYP on NK cell subsets,
there remains somequestion as to the effects on ILCs. Therefore, it is im-
portant to note differences between these studies. The Perry et al. and
Lin et al. studies, using freshly isolated blood, deﬁned circulating ILCs
as CD45+Lin− cells (CD3−CD14−CD19−CD11c−CD123−CD56−
CD20−); this deﬁnition of ILCs does not require CD127 expression, nor
does it exclude CD16-expressing cells, a population that includes
CD56−CD16+ NK cells (Björkström et al., 2010), from their analysis.
Further, Perry and colleagues classiﬁed all c-kit+RORγt+Lin− cells as
LTi cells; however, LTi-like ILC3s represent only a subset of total
c-kit+RORγt+ ILC3s (Spits et al., 2013). Of particular signiﬁcance for
the studies detailed here, there is clear consensus in the ILC ﬁeld that
CD127 expression is a cardinal feature of not only LTi cells (Cupedo
et al., 2009; Eberl and Littman, 2003; Mebius et al., 2001; Mebius
et al., 1997), but all ILC subsets (Hazenberg and Spits, 2014;
Sonnenberg et al., 2013; Spits et al., 2013). Our study uses current con-
sensus deﬁnitions to identify total ILCs as CD45+Lin−CD56−CD16−
CD127+, and deﬁne total ILC3s as T-bet−eomes−GATA-3loCCR6+ ILCs.
Based on the broader and more detailed analysis of ILC subsets in DAC
HYP-treated RRMS patients performed in these studies, we are able to
conﬁrm that DACHYP treatment does not appear to have any signiﬁcant
effects on any of the circulating ILC subsets, including LTi-like ILC3s.
One signiﬁcant advantage of the current study is the inclusion of a
placebo-treated patient population, which allowed the identiﬁcation
of potential changes in the ILC populations in RRMS patients over the
24-week study period. We observed no signiﬁcant changes in total
ILCs or in the three major subsets of ILCs in response to DAC HYP thera-
py, althoughwe observed a trend towards increased absolute number of
total ILCs between baseline and week 24; this increase did not achieve
statistical signiﬁcance (p = 0.1113) (Fig. 2B). The lack of effect on ma-
ture ILCswas perhapsmost strikingwhenwe analyzed the ILC2 popula-
tion, which expresses CD25 (Monticelli et al., 2011; Sonnenberg et al.,
2013). While several murine studies have demonstrated that IL-2 pro-
motes proliferation/survival and can enhance Th2 cytokine production
from ILC2s (Moro et al., 2010; Roediger et al., 2015), Neill, et al. reported
that IL-2 was neither sufﬁcient nor required for ILC2 proliferation
in vitro (Neill et al., 2010). Further, no study to date has addressed the
importance of endogenous IL-2 in ILC2 development and function
in vivo. Our own data in human patients demonstrate that despite de-
creased expression of CD25 on ILC2s, ILC2 numbers and frequencies
were not changed in MS patients treated with DAC HYP. These data
suggest that CD25-dependent IL-2 signaling does not play a major role
in the development or maintenance of ILC2s, in contrast to the role of
IL-2 in NK and regulatory T cell biology.Taken together, the data herein demonstrate that DACHYP has a sig-
niﬁcant impact on circulating NK cell populations but does not alter the
number or composition of circulating innate lymphoid cell populations.Appendix A. Supplementary data
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.jneuroim.2016.03.008.References
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